Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hypoxic cancer cells pose a great challenge to the oncologist because they are especially aggressive, metastatic, and resistant to therapy. Recently, we showed that elevation of the extracellular matrix protein lysyl oxidase (LOX) correlates with metastatic disease and is essential for hypoxia-induced metastasis. In an orthotopic rodent model of breast cancer, a small-molecule or antibody inhibitor of LOX abolished metastasis, offering preclinical validation of this enzyme as a therapeutic target.

Original publication

DOI

10.1158/0008-5472.CAN-06-3197

Type

Journal article

Journal

Cancer Res

Publication Date

01/11/2006

Volume

66

Pages

10238 - 10241

Keywords

Breast Neoplasms, Cell Hypoxia, Cell Proliferation, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Protein-Lysine 6-Oxidase